Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue
暂无分享,去创建一个
K. Hunt | R. Drezek | F. Meric-Bernstam | L. Middleton | J. Sun | R. J. Langsner | L. P. Middleton | F. Meric-Bernstam | K. K. Hunt | R. A. Drezek | T. K. Yu | T. Yu | T. Yu | J. Sun | Kelly K Hunt | F. Meric-Bernstam
[1] C. Perez. Conservation Therapy in T1‐T2 Breast Cancer: Past, Current Issues, and Future Challenges and Opportunities , 2003, Cancer journal.
[2] J. Nährig,et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] O. Warburg,et al. THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.
[4] G. Hortobagyi,et al. Positron emission tomography with fluorine‐18‐deoxyglucose in the detection and staging of breast cancer , 1993, Cancer.
[5] Timothy J. Muldoon,et al. Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy‐glucose , 2009, International journal of cancer.
[6] D. Schultz,et al. Outcomes in breast cancer patients relative to margin status after treatment with breast-conserving surgery and radiation therapy: the University of Pennsylvania experience. , 1999, International journal of radiation oncology, biology, physics.
[7] E. McDermott,et al. Positron emission tomography in the staging and management of breast cancer , 2004, The British journal of surgery.
[8] R L Wahl,et al. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] G. Weber,et al. Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissues. , 1955, Cancer research.
[10] J. Nährig,et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R L Wahl,et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1991, Radiology.
[12] Hideaki Matsuoka,et al. Measurement of Glucose Uptake and Intracellular Calcium Concentration in Single, Living Pancreatic β-Cells* , 2000, The Journal of Biological Chemistry.
[13] F. Penault-Llorca,et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? , 2006, British Journal of Cancer.
[14] R L Wahl,et al. An Immunohistochemical Study , 2006 .
[15] R. Drezek,et al. Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy , 2010, Breast Cancer Research and Treatment.
[16] P. Isaacson,et al. Immunoproliferative small-intestinal disease. An immunohistochemical study. , 1989, The American journal of surgical pathology.
[17] S. Singletary,et al. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy , 2007, Annals of Surgical Oncology.
[18] Alberto Luini,et al. The surgical margin status after breast-conserving surgery: discussion of an open issue , 2008, Breast Cancer Research and Treatment.
[19] J. Gazet,et al. The importance of the resection margin in conservative surgery for breast cancer. , 1996, European Journal of Surgical Oncology.
[20] George,et al. Glucose-6-phosphatase Activity in Normal, Precancerous, and Neoplastic Tissues* , 2006 .
[21] J. Mackey,et al. The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer , 2009, Current oncology.
[22] R. Weichselbaum,et al. Breast preservation in stage I and II carcinoma of the breast: The University of Chicago experience , 1996 .
[23] S. Jeffrey,et al. Predictors of reexcision findings and recurrence after breast conservation. , 2003, International journal of radiation oncology, biology, physics.
[24] M. Schwaiger,et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] Nizar Mullani,et al. Uptake of a Fluorescent Deoxyglucose Analog (2-NBDG) in Tumor Cells , 2005, Molecular Imaging and Biology.
[26] Paul J. van Diest,et al. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .
[27] J L Sunshine,et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.
[28] P. V. van Diest,et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] V. Chandramouli,et al. Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. , 2006, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.
[30] J. Vilcoq,et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. , 1989, International journal of radiation oncology, biology, physics.
[31] M E Phelps,et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. , 1992, Annals of surgery.
[32] L. Adler,et al. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. , 1997, Radiology.